New Compound MIK665 Targets MCL-1 to Treat Cancer
Researchers have identified a selective inhibitor that overcomes drug resistance in cancer cells.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Is now a good time to prioritize funding for experimental drug research over other health initiatives?
Scientists have developed MIK665, a small-molecule inhibitor designed to block MCL-1, a protein often responsible for therapeutic evasion in blood cancers. By targeting this protein, the compound aims to bypass the resistance mechanisms that often render cells unresponsive to existing treatments like venetoclax.
Why it matters
MCL-1 overexpression creates an anti-apoptotic pathway that allows cancer cells to survive current therapies. Successfully inhibiting this bypass may restore the effectiveness of treatments and improve outcomes for patients with hematologic malignancies.
The study utilized MIK665 to trigger the activation of executioner caspase-3 and caspase-7. Preclinical testing in murine xenograft models demonstrated that mitochondrial membrane potential dissipates within hours of exposure to the compound.
The players
MIK665
MIK665 is a selective small-molecule inhibitor designed to target the MCL-1 protein to prevent cancer cell survival.
The details
MIK665 functions by occupying the BH3-binding groove of MCL-1, which displaces pro-apoptotic effectors like BIM and NOXA. This process mobilizes BAX and BAK proteins to form oligomers on the outer mitochondrial membrane, ultimately triggering cytochrome c efflux and cell death.
Timeline
October 16, 2026: The research findings were published.
The Big Picture
This discovery marks a shift in how clinicians approach drug-resistant hematologic malignancies. It updates the efficacy parameters previously established by venetoclax therapy by addressing the MCL-1 bypass mechanism that limits its performance.
This development represents a potential future strategy for treating blood cancers that no longer respond to standard inhibitors. While not currently available, it suggests a path toward more durable treatment options for patients facing therapeutic evasion.
The takeaway
Targeting the MCL-1 protein serves as a promising strategy to counteract the anti-apoptotic defenses used by cancer cells. Continued investigation into these selective inhibitors is necessary to determine if they can safely transition from preclinical models to human applications.
Further reading
Learn more about the latest research and developments in Cancer.
Source note: This article includes information reported by Alwasat-ye.
Live Poll
Is now a good time to prioritize funding for experimental drug research over other health initiatives?
